Literature DB >> 22552220

Total hip arthroplasty for Crowe type Ⅳ developmental dysplasia.

Yukiharu Hasegawa1, Toshiki Iwase, Toshiya Kanoh, Taisuke Seki, Atsushi Matsuoka.   

Abstract

The purposes of this study were to evaluate the midterm clinical and radiographic results of total hip arthroplasty (THA) in patients with Crowe type IV developmental dysplasia and to evaluate whether low back pain would improve after THA. Eighteen consecutive patients (20 hips) were included in this study. The average age at the time of surgery was 58.5 years. The average follow-up was 10.2 years. The socket was placed at the level of the true acetabulum, and a femoral shortening osteotomy was performed. The average Harris hip score before surgery was improved from 56 to 85 points at the final follow-up. Revision was performed in 4 hips due to loosening of the femoral component in 1 hip and osteolysis in 3 hips. The midterm outcomes of THA in patients with Crowe type IV developmental dysplasia were satisfactory. The severity of low back pain was significantly reduced after THA.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22552220     DOI: 10.1016/j.arth.2012.02.026

Source DB:  PubMed          Journal:  J Arthroplasty        ISSN: 0883-5403            Impact factor:   4.757


  19 in total

1.  Total hip arthroplasty in the developmental dysplasia of the hip using transverse subtrochanteric osteotomy.

Authors:  Fırat Ozan; Erdal Uzun; Kaan Gürbüz; Şemmi Koyuncu; Taşkın Altay; Cemil Kayalı
Journal:  J Orthop       Date:  2016-06-24

2.  Lesser trochanteric osteotomy in total hip arthroplasty for treating CROWE type IV developmental dysplasia of hip.

Authors:  Nirong Bao; Jia Meng; Liwu Zhou; Ting Guo; Xiaofeng Zeng; Jianning Zhao
Journal:  Int Orthop       Date:  2013-01-05       Impact factor: 3.075

3.  Long-Term Results of Total Hip Arthroplasty with Step-Cut Osteotomy in Crowe Type IV Dysplastic Hips.

Authors:  Orhan Akıncı; Ali Turgut
Journal:  Indian J Orthop       Date:  2021-11-22       Impact factor: 1.251

4.  Reply to comment on Bao et al.: Lesser trochanteric osteotomy in total hip arthroplasty for treating CROWE type IV developmental dysplasia of hip.

Authors:  Bao Nirong; Zhao Jianning
Journal:  Int Orthop       Date:  2013-03-07       Impact factor: 3.075

5.  Total hip arthroplasty with a monoblock conical stem and subtrochanteric transverse shortening osteotomy in Crowe type IV dysplastic hips.

Authors:  Guido Grappiolo; Francesco La Camera; Antonello Della Rocca; Giuseppe Mazziotta; Giuseppe Santoro; Mattia Loppini
Journal:  Int Orthop       Date:  2018-09-05       Impact factor: 3.075

6.  Total Hip Arthroplasty for Crowe Type IV Developmental Dysplasia of the Hip Using a Titanium Mesh Cup and Subtrochanteric Femoral Osteotomy.

Authors:  Mengcun Chen; Daniel J Gittings; Shuhua Yang; Xianzhe Liu
Journal:  Iowa Orthop J       Date:  2018

7.  Comparison of transverse and modified subtrochanteric femoral shortening osteotomy in total hip arthroplasty for developmental dysplasia of hip: a meta-analysis.

Authors:  Changchuan Li; Chi Zhang; Maolin Zhang; Yue Ding
Journal:  BMC Musculoskelet Disord       Date:  2014-10-03       Impact factor: 2.362

8.  Subtrochanteric shortening osteotomy during cementless total hip arthroplasty in young patients with severe developmental dysplasia of the hip.

Authors:  Duan Wang; De-Hua Li; Qi Li; Hao-Yang Wang; Ze-Yu Luo; Yang Yang; Fu-Xing Pei; Zong-Ke Zhou
Journal:  BMC Musculoskelet Disord       Date:  2017-11-25       Impact factor: 2.362

9.  Low Reinfection Rates But a High Rate of Complications in THA for Infection Sequelae in Childhood: A Systematic Review.

Authors:  Rocco D'Apolito; Guido Bandettini; Gregorio Rossi; Filippo Piana Jacquot; Luigi Zagra
Journal:  Clin Orthop Relat Res       Date:  2021-05-01       Impact factor: 4.176

10.  Leg lengthening of more than 5 cm is a risk factor for sciatic nerve injury after total hip arthroplasty for adult hip dislocation.

Authors:  Yoshitoshi Higuchi; Yukiharu Hasegawa; Naoki Ishiguro
Journal:  Nagoya J Med Sci       Date:  2015-08       Impact factor: 1.131

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.